동물용 종양학 시장 규모, 점유율, 성장 분석 : 치료 유형별, 동물 유형별, 암 유형별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Veterinary Oncology Market Size, Share, Growth Analysis, By Therapy Type (Chemotherapy, Radiation Therapy), By Animal Type (Companion Animals, Livestock Animals), By Cancer Type, By End-User, By Region - Industry Forecast 2025-2032
동물용 종양학 시장 규모는 2023년 2,594억 달러로 평가되며, 2024년 2,907억 9,000만 달러에서 2032년 7,251억 4,000만 달러로 예측 기간(2025-2032년) 동안 12.10%의 CAGR로 성장할 것으로 예상됩니다.
동물용 종양학 시장은 반려동물의 암 발병률 증가와 동물 건강 관리에 대한 투자 증가로 인해 성장하고 있습니다. 반려동물 보호자들의 수의학적 치료에 대한 지출 의향 증가와 정부의 지원책은 이 시장을 발전시키는 중요한 추세입니다. 특히 미국수의사회는 반려견의 25%가 일생 동안 신생물과 마주하게 될 것으로 추정하고 있으며, 많은 경우 암이 사망 원인 중 1위로 꼽힙니다. 또한, COVID-19 사태는 반려동물과 보호자의 유대감을 강화하고 반려동물의 행복에 대한 주의를 환기시키고 있습니다. 이러한 추세는 새로운 치료법을 모색하는 수의학 임상 연구의 증가와 함께 강력한 성장 궤도를 의미합니다. 정부 지원 이니셔티브는 이러한 상황을 더욱 강화하여 동물 의료 분야에서 혁신적인 암 치료의 전망을 높이고 있습니다.
목차
소개
조사 방법
- 정보 조달
- 2차 데이터와 1차 데이터 방법
- 시장 규모 예측
- 시장 가정과 제한
주요 요약
- 세계 시장 전망
- 공급과 수요 동향 분석
- 부문별 기회 분석
시장 역학과 전망
- 시장 개요
- 시장 규모
- 시장 역학
- Porters 분석
주요 시장 인사이트
- 핵심성공요인
- 경쟁 정도
- 주요 투자 기회
- 시장 생태계
- 시장 매력 지수(2024년)
- PESTEL 분석
- 거시경제 지표
- 밸류체인 분석
- 가격 분석
- 규제 상황
- 사례 연구
동물용 종양학 시장 규모 : 치료 유형별
- 시장 개요
- 화학요법
- 방사선 치료
- 면역요법
- 수술
동물용 종양학 시장 규모 : 동물 유형별
- 시장 개요
- 반려동물
- 가축
- 소
- 양
- 돼지
동물용 종양학 시장 규모 : 암 유형별
- 시장 개요
- 림프종
- 비만세포암
- 악성 흑색종
- 유선암 및 편평상피암
- 기타
동물용 종양학 시장 규모 : 최종사용자별
- 시장 개요
- 동물 병원
- 수의 클리닉
- 조사기관
- 기타
동물용 종양학 시장 규모
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동 및 아프리카
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
경쟁 정보
- 상위 5개사의 비교
- 주요 기업의 시장 포지셔닝(2024년)
- 주요 시장 기업이 채용한 전략
- 시장의 최근 동향
- 기업의 시장 점유율 분석(2024년)
- 주요 기업 개요
- 기업 개요
- 제품 포트폴리오 분석
- 부문별 점유율 분석
- 매출 전년비 비교(2022-2024)
주요 기업 개요
- Zoetis Inc.(USA)
- Elanco Animal Health(USA)
- Boehringer Ingelheim(Germany)
- Merck Animal Health(USA)
- Virbac(France)
- Ceva Sante Animale(France)
- Vetoquinol(France)
- Dechra Pharmaceuticals(UK)
- IDEXX Laboratories(USA)
- Heska Corporation(USA)
- Aratana Therapeutics(USA)
- Karyopharm Therapeutics(USA)
- Regeneus Ltd.(Australia)
- PetCure Oncology(USA)
- Accuray Incorporated(USA)
- Varian Medical Systems(USA)
- Morphogenesis, Inc.(USA)
- Nippon Zenyaku Kogyo Co., Ltd.(Japan)
- Eli Lilly and Company(USA)
- Bayer AG(Germany)
결론과 추천사항
ksm
Veterinary Oncology Market size was valued at USD 259.4 Billion in 2023 and is poised to grow from USD 290.79 Billion in 2024 to USD 725.14 Billion by 2032, growing at a CAGR of 12.10% during the forecast period (2025-2032).
The veterinary oncology market is driven by the rising incidence of cancer among pets, coupled with growing investment in animal healthcare. Increased pet owner willingness to spend on veterinary treatment, along with supportive government initiatives, are significant trends propelling this market forward. Notably, the American Veterinary Medical Association estimates that 25% of dogs will face neoplasia in their lifetime, with cancer being the leading cause of death in many cases. Additionally, the COVID-19 pandemic has intensified the bond between pets and owners, promoting greater focus on pet well-being. This trend, combined with an increase in veterinary clinical studies exploring new treatments, signifies a robust growth trajectory. Government-backed initiatives further bolster this landscape, enhancing prospects for innovative cancer therapies in veterinary medicine.
Top-down and bottom-up approaches were used to estimate and validate the size of the Veterinary Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Veterinary Oncology Market Segmental Analysis
Global Veterinary Oncology Market is segmented by therapy type, animal type, cancer type, end-user and region. Based on therapy type, the market is segmented into chemotherapy, radiation therapy, immunotherapy and surgery. Based on animal type, the market is segmented into companion animals and livestock animals. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer and others. Based on end-user, the market is segmented into veterinary hospitals, veterinary clinics, research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Veterinary Oncology Market
One of the primary factors propelling the veterinary oncology market is the increasing occurrence of cancer among companion animals, including dogs and cats. With pets enjoying longer life expectancies, they face similar health challenges as humans, particularly the risk of cancer as they age. This surge in cancer cases among pets has led to a heightened demand for advanced and effective oncology treatments. As pet owners become more aware of the importance of specialized cancer care, the need for innovative therapies and diagnostic solutions in veterinary oncology continues to grow, significantly boosting the market's expansion and development.
Restraints in the Veterinary Oncology Market
The veterinary oncology market faces notable restraints due to the high costs associated with cancer treatments for pets. Many pet owners find the expenses related to diagnostic tests, surgical procedures, medications, and ongoing follow-up care to be significant financial burdens. This elevated pricing can limit the accessibility of veterinary oncology services, making it challenging for some pet owners to pursue necessary treatments for their beloved animals. Ultimately, the financial constraints associated with veterinary oncology can deter pet owners from seeking potentially life-saving interventions, thereby impacting the overall growth and reach of this specialized market.
Market Trends of the Veterinary Oncology Market
The veterinary oncology market is witnessing a significant trend towards personalized medicine, mirroring advancements in human cancer care. As pet owners increasingly seek tailored treatment options, veterinary oncologists are focusing on customized interventions based on the unique genetic profiles and biomarkers of individual animals' cancers. This shift not only enhances treatment efficacy but also aims to reduce potential adverse effects, leading to improved quality of life for pets. The integration of advanced diagnostics and targeted therapies is expected to drive innovation in the market, ultimately expanding growth opportunities for veterinary oncology practitioners and contributing to the broader field of animal health.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Regulatory Landscape
- Case Studies
Global Veterinary Oncology Market Size by Therapy Type & CAGR (2025-2032)
- Market Overview
- Chemotherapy
- Oral Chemotherapy
- Injectable Chemotherapy
- Radiation Therapy
- External Beam Radiation Therapy
- Internal Radiation Therapy
- Immunotherapy
- Monoclonal Antibodies
- Cancer Vaccines
- Surgery
- Tumor Removal
- Reconstructive Surgery
Global Veterinary Oncology Market Size by Animal Type & CAGR (2025-2032)
- Market Overview
- Companion Animals
- Livestock Animals
Global Veterinary Oncology Market Size by Cancer Type & CAGR (2025-2032)
- Market Overview
- Lymphoma
- Mast Cell Cancer
- Melanoma
- Mammary And Squamous Cell Cancer
- Others
Global Veterinary Oncology Market Size by End-User & CAGR (2025-2032)
- Market Overview
- Veterinary Hospitals
- Veterinary Clinics
- Research Institutes
- Others
Global Veterinary Oncology Market Size & CAGR (2025-2032)
- North America (Therapy Type, Animal Type, Cancer Type, End-User)
- Europe (Therapy Type, Animal Type, Cancer Type, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapy Type, Animal Type, Cancer Type, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapy Type, Animal Type, Cancer Type, End-User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapy Type, Animal Type, Cancer Type, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- Zoetis Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Elanco Animal Health (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck Animal Health (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Virbac (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ceva Sante Animale (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vetoquinol (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dechra Pharmaceuticals (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IDEXX Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Heska Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aratana Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Karyopharm Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Regeneus Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PetCure Oncology (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Accuray Incorporated (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Varian Medical Systems (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Morphogenesis, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nippon Zenyaku Kogyo Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
